Literature DB >> 24515997

Effect of genetic subtypes and growth hormone treatment on bone mineral density in Prader-Willi syndrome.

Manaswitha Khare, June-Anne Gold, Marie Wencel, John Billimek, Abhilasha Surampalli, Bridgette Duarte, Andria Pontello, Pietro Galassetti, Suzanne Cassidy, Virginia E Kimonis.   

Abstract

UNLABELLED: Abstract Background: Currently, there is limited information on the effects of growth hormone and of the different genetic subtypes on bone mineral density (BMD) in Prader-Willi syndrome (PWS).
METHODS: We evaluated BMD in 79 individuals with the common subtypes of PWS (48 with deletion and 27 with UPD) and the effect of growth hormone treatment (n=46) vs. no growth hormone treatment.
RESULTS: Forty-four percent of the individuals studied had whole body, hip, or spine BMD <-1 standard deviation (SD) and 10% had a BMD <-2 SD. BMD Z-scores and total BMD (g/cm2) of the spine were significantly higher in the growth hormone group. With each year of growth hormone treatment, these values increased by a factor of 0.207 and 0.011 (p=0.006 and 0.032), respectively. Individuals with uniparental disomy revealed higher spine BMD compared with deletion subclass; however, the differences were not significant.
CONCLUSION: This study emphasizes the importance of evaluating bone mineralization in individuals with PWS and the beneficial effects of prolonged treatment with growth hormone. There was a trend for a higher BMD in individuals with uniparental disomy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24515997     DOI: 10.1515/jpem-2013-0180

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  6 in total

1.  Contributing factors of mortality in Prader-Willi syndrome.

Authors:  Jennifer Proffitt; Kathryn Osann; Barbara McManus; Virginia E Kimonis; Janalee Heinemann; Merlin G Butler; David A Stevenson; June-Anne Gold
Journal:  Am J Med Genet A       Date:  2018-12-19       Impact factor: 2.802

2.  Anthropometric adjustments are helpful in the interpretation of BMD and BMC Z-scores of pediatric patients with Prader-Willi syndrome.

Authors:  T N Hangartner; D F Short; T Eldar-Geva; H J Hirsch; M Tiomkin; A Zimran; V Gross-Tsur
Journal:  Osteoporos Int       Date:  2016-07-04       Impact factor: 4.507

3.  Impact of transitional care on endocrine and anthropometric parameters in Prader-Willi syndrome.

Authors:  A C Paepegaey; M Coupaye; A Jaziri; F Ménesguen; B Dubern; M Polak; J M Oppert; M Tauber; G Pinto; C Poitou
Journal:  Endocr Connect       Date:  2018-04-17       Impact factor: 3.335

4.  Early Diagnosis in Prader-Willi Syndrome Reduces Obesity and Associated Co-Morbidities.

Authors:  Virginia E Kimonis; Roy Tamura; June-Anne Gold; Nidhi Patel; Abhilasha Surampalli; Javeria Manazir; Jennifer L Miller; Elizabeth Roof; Elisabeth Dykens; Merlin G Butler; Daniel J Driscoll
Journal:  Genes (Basel)       Date:  2019-11-06       Impact factor: 4.096

Review 5.  Growth hormone therapy for Prader-willi syndrome: challenges and solutions.

Authors:  Graziano Grugni; Alessandro Sartorio; Antonino Crinò
Journal:  Ther Clin Risk Manag       Date:  2016-06-02       Impact factor: 2.423

6.  Relative Contributions of Lean and Fat Mass to Bone Mineral Density: Insight From Prader-Willi Syndrome.

Authors:  Alexander Viardot; Louise Purtell; Tuan V Nguyen; Lesley V Campbell
Journal:  Front Endocrinol (Lausanne)       Date:  2018-08-22       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.